# A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease

> **NCT06388564** · PHASE2 · RECRUITING · sponsor: **Incyte Corporation** · enrollment: 120 (estimated)

## Conditions studied

- Chronic Graft-versus-host-disease

## Interventions

- **DRUG:** Axatilimab
- **DRUG:** Ruxolitinib
- **DRUG:** Corticosteroids

## Key facts

- **NCT ID:** NCT06388564
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-11
- **Primary completion:** 2027-06-01
- **Final completion:** 2029-12-01
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06388564

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06388564, "A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06388564. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*